Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: A prospective, observational, international, multi-centre study

Health and Quality of Life Outcomes

Volumn 8, Issue , 2010, Pages

  Jongen, Peter J ^a   Lehnick, Dirk ^b   Sanders, Evert ^c   Seeldrayers, Pierette ^d   Fredrikson, Sten ^e   Andersson, Magnus ^f   Speck, Joachim ^g  

^a MS4 Research Institute   (Netherlands)

^b Hohentengen am Hochrhein ^*  (Germany)

^c AMPHIA HOSPITAL   (Netherlands)

^d Hospital Civil Charleroi   (Belgium)

^e KAROLINSKA INSTITUTE   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g Nuvisan GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; METHOTREXATE; MITOXANTRONE; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; DEMOGRAPHY; DEPRESSION; DISABILITY; DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FATIGUE IMPACT SCALE; FEMALE; HUMAN; IMMUNOMODULATION; LEEDS MULTIPLE SCLEROSIS QUALITY OF LIFE SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; QUALITY OF LIFE; RELAPSE; UNSPECIFIED SIDE EFFECT; DOSE RESPONSE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDY; PSYCHOLOGY; PSYCHOMETRY; QUALITATIVE RESEARCH; QUESTIONNAIRE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PROSPECTIVE STUDIES; PSYCHOMETRICS; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 78149450871     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-8-133     Document Type: Article

References (29)

1. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
2. Comi G, Filippi M, Wolinskt JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001, 49:290-297. 10.1002/ana.64, 11261502.
3. Metz LM, Patten SB, Archibald CJ, Bakker JI, Harris CJ, Patry DG, Bell RB, Yeung M, Murphy WF, Stoian CA, Billesberger K, Tillotson L, Peters S, McGowan D. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psych 2004, 75:1045-1047.
4. Ziemssen T, Hoffman J, Apfel R, Kern S. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes 2008, 6:67. 10.1186/1477-7525-6-67, 2542355, 18775064.
5. Hadjimicheal O, Vollmer T, Oleen-Burkey M, . North American Research Committee on Multiple Sclerosis Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes 2008, 14:100. North American Research Committee on Multiple Sclerosis.
6. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007, 13:245-261.
7. Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD, Brown M. Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population. Value Health 2009,
8. Lily O, McFadden E, Hensor E, Johnson M, Ford H. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatement. Mult Scler 2006, 12:808-813. 10.1177/1352458506070946, 17263011.
9. Jongen PJ, Sindic C, Carton H, Zwanikken C, Lemmens W, Borm G. Functional composite and quality of Life in Avonex-treated Relapsing multiple sclerosis patients (FLAIR) study group: Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. J Neurol 2010, 257:584-589. 10.1007/s00415-009-5378-x, 19921303.
10. Guarnaccia JB, Aslan M, O'Connor TZ, Hope M, Kazis L, Kashner CM, Booss J. Quality of life for veterans with multiple sclerosis on disease-modifying agents: Relationship to disability. J Rehabil Res Dev 2006, 43:25-44. 10.1682/JRRD.2006.11.0139, 16847769.
11. Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 2009, 277(Suppl 1):S37-41. 10.1016/S0022-510X(09)70011-5, 19200865.
12. Krupp LB. Mechanisms, measurement, and management of fatigue in multiple sclerosis. Multiple sclerosis: clinical challenges and controversies 1997, 283-294. London, Martin Dunitz, Thompson AJ, Polman C, Hohlfeld R.
13. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994, 21:9-14.
14. Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler 2000, 6:115-120.
15. Zwibel HL, . Copolymer-1 Treatment Study Principal Investigators Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurol Scand 2006, 113:378-86. 10.1111/j.1600-0404.2006.00627.x, 16674604, Copolymer-1 Treatment Study Principal Investigators.
16. Ministerie van Volksgezondheid, Welzijn en Sport. Dutch Medical Research Involving Human Subjects Act (WMO). International Publication Series Health, Welfare and Sport nr.2. The Hague 2000,
17. Ford HL, Gerry E, Tennant A, Whally D, Haigh R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil 2001, 15:247-25. 10.1191/026921501673658108, 11386394.
18. Ford HL, Gerry E, Johnson MH, Tennant A. Health status and quality of life of people with multiple sclerosis. Disabil Rehabil 2001, 23:516-521. 10.1080/09638280010022090, 11432648.
19. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Lif Res 1995, 4:187-206.
20. Ford HL, Eyres S, Tennant A. Measuring change in multiple sclerosis: responsiveness of three outcome measures. J Neurol Sci 2001, 187:S456.
21. Greenhaigh J, Ford AF, Long AF, Hurst K. The MS symptom and impact diary (MSSID): psychometric evaluation of a new instrument to measure the day to day impact of multiple sclerosis. J Neurol Neurosurg Psychiatry 2004, 75:577-82. 10.1136/jnnp.2003.020529, 1739024, 15026500.
22. Fisk JD, Ritvo PG, Rossi L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of impact scale. Clin Infect Dis 1994, 18(Suppl 1):S79-83.
23. Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, Fieschi C. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 2004, 218:103-108. 10.1016/j.jns.2003.11.005, 14759641.
24. Beck AT, Rial WY, Rickels K. Short form of depression inventory: cross-validation. Psychol Rep 1974, 34:1184-1186.
25. Moran PJ, Mohr DC. The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. J Behav Med 2005, 28:35-41. 10.1007/s10865-005-2561-0, 15887874.
26. Sharrack B, Hughes RAC. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 1999, 5:223-233.
27. Hoogervorst ELJ, Van Winsen LML, Eikelboom MJ, Kalkers NF, Uitdehaag BMJ, Polman CH. Comparisons of patient self-report, neurologic examination, and functional impairment in MS. Neurology 2001, 56:934-937.
28. Mitchell AJ, Benito-Sanchez J, Gonzalez JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005, 4:556-566. 10.1016/S1474-4422(05)70166-6, 16109362.
29. Arnoldus JH, Killestein J, Pfennings LE, Jelles B, Uitdehaag BM, Polman CH. Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler 2000, 6:338-342.